Skip to main content

Advertisement

SpringerLink
Log in

Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy

  • Review
  • Published:
Tumor Biology

Abstract

Topoisomerases are nuclear enzymes that regulate topology of DNA by facilitating the temporary cleavage and ligation cycle of DNA. Among all forms of topoisomerases, TOP-IIA is extensively associated with cell proliferation and therefore is an important therapeutic target in diseases that involved cellular proliferation such as cancers. Nearly half of present-day antitumor regimens contain at least one prescription that act as a topoisomerase inhibitor. Generally, tumor cells show divergent expression of TOP-IIA compared to normal cells. The remarkable expression of TOP-IIA in various carcinomas provides a significant biomarker toward understanding the nature of malignancy. TOP-IIA expression and amplification studies help in diagnosing cancer and to observe the disease progression, overall survival (OS) of patients, and response to therapy. This review highlights the research output and analysis in exploring the standing of TOP-IIA in various carcinomas. As some reports show contradiction within the same field of interest, the outline of that may help to induce researchers for further investigation and clarification. To the best of our knowledge, this is the first overview briefly summarizing the prognostic feature of TOP-IIA in various types of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bromberg KD, Osheroff N. Mechanism of action of topoisomerase II-targeted anticancer drugs. DNA Topoisomerases in Cancer Therapy: Springer; 2003. p. 53–78.

  2. Wang JC. DNA topoisomerases. Annu Rev Biochem. 1996;65(1):635–92.

    Article  CAS  PubMed  Google Scholar 

  3. Thakur DS. Topoisomerase II, inhibitors in cancer treatment. Int J Pharm Sci Nanotechnol. 2011;3(4):1173–81.

    CAS  Google Scholar 

  4. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001;70(1):369–413.

    Article  CAS  PubMed  Google Scholar 

  5. Wang JC. Reflections on an accidental discovery. DNA Topoisomerases in Cancer Therapy: Springer; 2003. p. 1–13.

  6. Pommier Y, Barceló J, Furuta T, Takemura H, Sordet O. Mechanisms of topoisomerase I inhibition by anticancer drugs. DNA Topoisomerases in Cancer Therapy: Springer; 2003. p. 15–52.

  7. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases i. Biochim Biophys Acta Gene Struct Expr. 1995;1262(1):1–14.

    Article  Google Scholar 

  8. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17(5):421–33.

    Article  CAS  PubMed  Google Scholar 

  9. Higgins NP. A human TOP2A core DNA binding X-ray structure reveals topoisomerase subunit dynamics and a potential mechanism for SUMO modulation of decatenation. J Mol Biol. 2012;424(3):105–8.

    Article  CAS  PubMed  Google Scholar 

  10. Lin Y-S, Huang W-C, Chen M-S, Hsieh T-s. Toward discovering new anti-cancer agents targeting topoisomerase IIα: a facile screening strategy adaptable to high throughput platform. 2014.

  11. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta Gene Struct Expr. 1998;1400(1):155–71.

    Article  CAS  Google Scholar 

  12. Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer. 2009;9(5):327–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv Cancer Res. 2001;80:189–216.

    Article  CAS  PubMed  Google Scholar 

  14. Wu S-Y, Pan S-L, Xiao Z-Y, Hsu J-L, Chen M-C, Lee K-H, et al. NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and Ros generation in human renal carcinoma cells. 2014.

  15. Hajji N, Pastor N, Mateos S, Cortés F. DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193. Mutat Res Fundam Mol Mech Mutagen. 2003;530(1):35–46.

    Article  CAS  Google Scholar 

  16. Shastry B. Overexpression of genes in health and sickness. A bird’s eye view. Comp Biochem Physiol B Biochem Mol Biol. 1995;112(1):1–13.

    Article  CAS  PubMed  Google Scholar 

  17. Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM. The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol. 2012;424(3):109–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Belluti S, Basile V, Benatti P, Ferrari E, Marverti G, Imbriano C. Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells. Cell Death Dis. 2013;4(8):e756.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kim E-J, Lee Y-S, Kim Y-J, Kim M-J, Ha Y-S, Jeong P, et al. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology. 2010;75(6):1516.e9–13.

    Article  Google Scholar 

  20. Davies SL, Popert R, Coptcoat M, Hickson ID, Masters JR. Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II α and β genes. Int J Cancer. 1996;65(1):63–6.

    Article  CAS  PubMed  Google Scholar 

  21. Koren R, Kugel V, Dekel Y, Weissman Y, Livne P, Gal R. Human DNA topoisomerase‐IIα expression as a prognostic factor for transitional cell carcinoma of the urinary bladder. BJU Int. 2003;91(6):489–92.

    Article  CAS  PubMed  Google Scholar 

  22. Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, et al. HER‐2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer. 2003;107(5):764–72.

    Article  CAS  PubMed  Google Scholar 

  23. Ben Abdelkrim S, Rammeh S, Ziadi S, Tlili T, Jaidane M, Mokni M. Expression of topoisomerase II alpha, ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma. J Immunoass Immunochem. 2014;35(4):358–67.

    Article  CAS  Google Scholar 

  24. Monnin KA, Bronstein IB, Gaffney DK, Holden JA. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol. 1999;30(4):384–91.

    Article  CAS  PubMed  Google Scholar 

  25. Van der Zee A, De Vries E, Hollema H, Kaye S, Brown R, Keith WN. Molecular analysis of the topoisomerase II α gene and its expression in human ovarian cancer. Ann Oncol. 1994;5(1):75–81.

    Article  PubMed  Google Scholar 

  26. Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, et al. Topoisomerase IIα mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol. 2009;22(4):579–88.

    Article  CAS  PubMed  Google Scholar 

  27. Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, et al. Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients. Br J Cancer. 2008;98(12):1910–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocellular Carcinoma. 2014;1:115–25.

    Article  Google Scholar 

  29. Wong N, Yeo W, Wong WL, Wong NLY, Chan KYY, Mo FKF, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2009;124(3):644–52.

    Article  CAS  PubMed  Google Scholar 

  30. Watanuki A, Ohwada S, Fukusato T, Makita F, Yamada T, Kikuchi A, et al. Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma. Anticancer Res. 2001;22(2B):1113–9.

    Google Scholar 

  31. Panvichian R, Tantiwetrueangdet A, Angkathunyakul N, Leelaudomlipi S. TOP2A amplification and overexpression in hepatocellular carcinoma tissues. BioMed Res Int. 2015;2015.

  32. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang J-M, Hait WN. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res. 1998;4(6):1393–403.

    CAS  PubMed  Google Scholar 

  33. Willman JH, Holden JA. Immunohistochemical staining for DNA topoisomerase II‐alpha in benign, premalignant, and malignant lesions of the prostate. Prostate. 2000;42(4):280–6.

    Article  CAS  PubMed  Google Scholar 

  34. Hughes C, Murphy A, Martin C, Fox E, Ring M, Sheils O, et al. Topoisomerase II-α expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma. J Clin Pathol. 2006;59(7):721–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B, O’Leary JJ, et al. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res. 2007;67(6):2893–8.

    Article  CAS  PubMed  Google Scholar 

  36. De Resende MF, Vieira S, Chinen L, Chiappelli F, da Fonseca FP, Guimarães GC, et al. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 2013;11(1):1–9.

    Article  Google Scholar 

  37. Hasby E, Saied E. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia. J Egypt Natl Canc Inst. 2008;20(2):158–67.

    PubMed  Google Scholar 

  38. da Cunha IW, De Brot L, Carvalho KC, Rocha RM, Fregnani JH, Falzoni R, et al. Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2/neu, and survivin. Ann Surg Oncol. 2012;19(6):1790–9.

    Article  PubMed  Google Scholar 

  39. Gogou PN, Batistatou A, Pakos EE, Apostolikas N, Stefanou D, Tsekeris PG. Expression of E-cadherin, β-catenin and topoisomerase IIα in leiomyosarcomas. Clin Transl Oncol. 2009;11(8):548–51.

    Article  CAS  PubMed  Google Scholar 

  40. Ptaszyński K, Szumera-Ciećkiewicz A, Zakrzewska K, Tuziak T, Mrozkowiak A, Rutkowski P. HER2, EGFR and TOPIIA gene amplification and protein expression in synovial sarcoma before and after combined treatment. Pol J Pathol. 2009;1:10–8.

    Google Scholar 

  41. Endo H, Hirokawa M, Ishimaru N, Tanaka Y, Yamashita M, Sakaki M, et al. Unique cell membrane expression of topoisomerase‐II alpha as a useful diagnostic marker of liposarcoma. Pathol Int. 2004;54(3):145–50.

    Article  CAS  PubMed  Google Scholar 

  42. Zhao H, Yu H, Liu Y, Wang Y, Cai W. DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival. Clin Neuropathol. 2007;27(2):83–90.

    Google Scholar 

  43. Hong Y, Sang M, Shang C, Xue Y-x, Liu Y-h. Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells. Neurosci Lett. 2012;518(2):138–43.

    Article  CAS  PubMed  Google Scholar 

  44. Miettinen H, Järvinen T, Kellner U, Kauraniemi P, Parwaresch R, Rantala I, et al. High topoisomerase IIα expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol. 2000;26(6):504–12.

    Article  CAS  PubMed  Google Scholar 

  45. Shamaa AA, Zyada MM, Wagner M, Awad SS, Osman MM, Azeem AAA. The significance of Epstein Barr virus (EBV) & DNA topoisomerase II alpha (DNA-Topo II alpha) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC). Diagn Pathol. 2008;3:45.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Hanagiri T, Ono K, Kuwata T, Takenaka M, Oka S, Chikaishi Y, et al. Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer. J UOEH. 2011;33(3):205–16.

    Article  CAS  PubMed  Google Scholar 

  47. Xu X-L, Zheng W-H, Fu Z-X, Li Z-P, Xie H-X, Li X-X, et al. Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas. Med Oncol. 2015;32(1):1–9.

    Article  Google Scholar 

  48. Ohashi Y, Sasano H, Yamaki H, Shizawa S, Kikuchi A, Shineha R, et al. Topoisomerase II alpha expression in esophageal squamous cell carcinoma. Anticancer Res. 1998;19(3A):1873–80.

    Google Scholar 

  49. Lan J, Huang H-Y, Lee S-W, Chen T-J, Tai H-C, Hsu H-P, et al. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma. Tumor Biol. 2014;35(1):179–87.

    Article  CAS  Google Scholar 

  50. Feng Y, Zhang H, Gao W, Wen S, Huangfu H, Sun R, et al. Expression of DNA topoisomerase II-α: clinical significance in laryngeal carcinoma. Oncol Lett. 2014;8(4):1575–80.

    PubMed  PubMed Central  Google Scholar 

  51. Chiu C-F, Chow K-C, Lin F-M, Lin CK, Liu S-M, Chen KY. Expression of DNA topoisomerase IIα and multidrug resistance p-glycoprotein in acute leukemia. Chin Med J (Taipei). 1997;60:184–90.

    CAS  Google Scholar 

  52. Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, Korkolopoulou P, Angelopoulou MK, Siakantaris MP, et al. Topoisomerase IIα expression as an independent prognostic factor in Hodgkin’s lymphoma. Clin Cancer Res. 2008;14(6):1759–66.

    Article  CAS  PubMed  Google Scholar 

  53. Tretiakova M, Turkyilmaz M, Grushko T, Kocherginsky M, Rubin C, Teh B, et al. Topoisomerase IIα in Wilms’ tumour: gene alterations and immunoexpression. J Clin Pathol. 2006;59(12):1272–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Tsiambas E, Karameris A, Tiniakos DG, Karakitsos P. Evaluation of topoisomerase IIa expression in pancreatic ductal adenocarcinoma: a pilot study using chromogenic in situ hybridization and immunohistochemistry on tissue microarrays. Pancreatology. 2007;7(1):45–52.

    Article  CAS  PubMed  Google Scholar 

  55. Liang Z, Wang W, Gao J, Wu S, Zeng X, Liu T. Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas. Zhonghua Bing Li Xue Za Zhi Chin J Pathol. 2007;36(2):102–6.

    CAS  Google Scholar 

  56. Manaios L, Tsiambas E, Alevizaki M, Karameris A, Alexopoulou D, Lambropoulou S, et al. Comparative topoisomerase IIa and ki 67 protein expression in papillary thyroid carcinoma based on tissue microarrays and image analysis. J BUON. 2007;13(4):537–41.

    Google Scholar 

  57. Yan S, Shun-Chang J, Li C, Jie L, Ya-Li L, Ling-Xiong W. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. BMC Cancer. 2010;10(1):621.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Schrader C, Meusers P, Brittinger G, Teymoortash A, Siebmann J, Janssen D, et al. Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia. 2004;18(7):1200–6.

    Article  CAS  PubMed  Google Scholar 

  59. Albadine R, Wang W, Brownlee NA, Toubaji A, Billis A, Argani P, et al. Topoisomerase II α status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. J Urol. 2009;182(2):735–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Schaeffer EM, Guzzo TJ, Furge KA, Netto G, Westphal M, Dykema K, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase‐inhibiting therapy. BJU Int. 2010;106(1):62–5.

    Article  PubMed  Google Scholar 

  61. Jain M, Zhang L, He M, Zhang Y-Q, Shen M, Kebebew E. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013;20(3):361–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Stromar IK, Jakic-Razumovic J. The value of immunohistochemical determination of topoisomerase iiα and ki67 as markers of cell proliferation and malignant transformation in colonic mucosa. Appl Immunohistochem Mol Morphol. 2014;22(7):524–9.

    Article  CAS  PubMed  Google Scholar 

  63. Kim R, Ohi Y, Inoue H, Toge T. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers. Anticancer Res. 1998;19(6B):5393–8.

    Google Scholar 

  64. Yang F, Jia Z. Expression of topoisomerase II alpha in human colorectal carcinoma and its significance. Nan fang yi ke da xue xue bao J South Med Univ. 2010;30(8):1959–61. 64.

    CAS  Google Scholar 

  65. Liming S, Yuan Z, Qinghua D, Lei W, Qifeng J, Haojie L. Human epidermal growth factor receptor-2 and topoisomerase II alpha expressions in rectal cancer. Hepatogastroenterology. 2010;58(106):359–63.

    Google Scholar 

  66. Gao XH, Yu ZQ, Zhang C, Bai CG, Zheng JM, Fu CG. DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner. Int J Colorectal Dis. 2012;27(4):429–35.

    Article  PubMed  Google Scholar 

  67. Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, Kokkola A, et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer. 2004;109(4):548–53.

    Article  CAS  PubMed  Google Scholar 

  68. Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A. Topoisomerase IIα gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol. 2006;37(10):1333–43.

    Article  CAS  PubMed  Google Scholar 

  69. Tanner M, Hollmen M, Junttila T, Kapanen A, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8.

    Article  CAS  PubMed  Google Scholar 

  70. Liu H-Q, Zhang S-L, Song S. HER-2/neu and TOPIIa expression in gastric cancer reflect disease severity. Hepatogastroenterology. 2012;59(116):1290–3.

    CAS  PubMed  Google Scholar 

  71. Sekine I, Shimizu C, Nishio K, Saijo N, Tamura T. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int J Clin Oncol. 2009;14(2):112–9.

    Article  CAS  PubMed  Google Scholar 

  72. El Rebey HS, Aiad HA, Asaad NY, Abd El-Wahed MM, Abulkheir IL, Abulkasem FM, et al. Immunohistochemical expression of topoisomerase II a and tissue inhibitor of metalloproteinases 1 in locally advanced breast carcinoma. Menoufia Med J. 2014;27(1):1.

    Article  Google Scholar 

  73. Huang L, Chen T, Chen C, Chen S, Liu Y, Wu J, et al. Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. World J Surg Oncol. 2013;11(1):1–9.

    Article  Google Scholar 

  74. Mrklic I, Pogorelic Z, Capkun V, Tomic S. Expression of topoisomerase II-α in triple negative breast cancer. Appl Immunohistochem Mol Morphol. 2014;22(3):182–7.

    Article  CAS  PubMed  Google Scholar 

  75. Żaczek A, Markiewicz A, Supernat A, Bednarz-Knoll N, Brandt B, Seroczyńska B, et al. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer. Pathol Oncol Res. 2012;18(4):885–94.

    Article  PubMed  Google Scholar 

  76. Zhu L, Li Y-F, Chen W-G, He J-R, Peng C-H, Zhu Z-G, et al. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Chin Med J. 2008;121(20):1965–8.

    PubMed  Google Scholar 

  77. Biesaga B, Niemiec J, Ziobro M, Wysocka J, Kruczak A. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy. Breast. 2011;20(4):338–50.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge The Ministry of Science, Technology, and Innovation MOSTI Malaysia (06-01-08-SF0147) for supporting the research team.

Author information

Authors and Affiliations

  1. Kulliyyah of Science, International Islamic University Malaysia, Bandar Indera Mahkota, 25200, Kuantan, Pahang, Malaysia

    Yousaf Ali & Shafida Abd Hamid

Authors
  1. Yousaf Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shafida Abd Hamid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shafida Abd Hamid.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ali, Y., Abd Hamid, S. Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy. Tumor Biol. 37, 47–55 (2016). https://doi.org/10.1007/s13277-015-4270-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4270-9

Keywords

Search

Navigation